For the analysis, AHIP examined the 10 largest pharmaceutical companies by revenue in 2020 and used their annual reports and other financial filings to compare money spent on research and development to money spent on selling, general and administrative costs.
Selling and marketing expenses exceeded research and development costs by $36 billion, or 37 percent, for the group as a whole, the analysis found.
GlaxoSmithKline spent $15 billion on sales and marketing in 2020 compared with $7 billion on research and development. Bayer spent $18 billion on sales and marketing compared with $8 billion for research and development. Johnson & Johnson spent $22 billion on sales and marketing, compared with $12 billion on research and development.
The three drugmakers that spent more on research and development than on sales and marketing were Bristol Myers Squibb, Merck and Roche. The other drugmakers included in the analysis were AbbVie, Novartis, Pfizer and Sanofi.
Find the full analysis here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
